|
1
|
van Gelder T, Baan CC, Balk AH, et al:
Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a
monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the
development of acute heart allograft rejection in humans.
Transplantation. 65:405–410. 1998.PubMed/NCBI
|
|
2
|
Li XC, Roy-Chaudhury P, Hancock WW, et al:
IL-2 and IL-4 double knockout mice reject islet allografts: a role
for novel T cell growth factors in allograft rejection. J Immunol.
161:890–896. 1998.PubMed/NCBI
|
|
3
|
Steiger J, Nickerson PW, Steurer W,
Moscovitch-Lopatin M and Strom TB: IL-2 knockout recipient mice
reject islet cell allografts. J Immunol. 155:489–498.
1995.PubMed/NCBI
|
|
4
|
Lewis EC, Weiler M, Tejman-Yarden N, et
al: Involvement of graft-derived interleukin-15 in islet allograft
rejection in mice. Cytokine. 34:106–113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng XX, Gao W, Donskoy E, et al: An
antagonist mutant IL-15/Fc promotes transplant tolerance.
Transplantation. 81:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikemizu S, Chirifu M and Davis SJ: IL-2
and IL-15 signaling complexes: different but the same. Nat Immunol.
13:1141–1142. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ring AM, Lin JX, Feng D, et al:
Mechanistic and structural insight into the functional dichotomy
between IL-2 and IL-15. Nat Immunol. 13:1187–1195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Waldmann TA: The IL-2/IL-15 receptor
systems: targets for immunotherapy. J Clin Immunol. 22:51–56. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grabstein KH, Eisenman J, Shanebeck K, et
al: Cloning of a T cell growth factor that interacts with the beta
chain of the interleukin-2 receptor. Science. 264:965–968. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Sabatino A, Calarota SA, Vidali F,
MacDonald TT and Corazza GR: Role of IL-15 in immune-mediated and
infectious diseases. Cytokine Growth Factor Rev. 22:19–33.
2011.PubMed/NCBI
|
|
11
|
van Es T, van Puijvelde GH, Michon IN, et
al: IL-15 aggravates atherosclerotic lesion development in LDL
receptor deficient mice. Vaccine. 29:976–983. 2011.PubMed/NCBI
|
|
12
|
d‘Ettorre G, Andreotti M, Ceccarelli G, et
al: The role of IL-15 in challenging Acquired Immunodeficiency
Syndrome. Cytokine. 57:54–60. 2012.PubMed/NCBI
|
|
13
|
Croce M, Orengo AM, Azzarone B and Ferrini
S: Immunotherapeutic applications of IL-15. Immunotherapy.
4:957–969. 2012. View Article : Google Scholar
|
|
14
|
Roberti MP, Rocca YS, Amat M, et al: IL-2-
or IL-15-activated NK cells enhance Cetuximab-mediated activity
against triple-negative breast cancer in xenografts and in breast
cancer patients. Breast Cancer Res Treat. 136:659–671. 2012.
View Article : Google Scholar
|
|
15
|
Steel JC, Waldmann TA and Morris JC:
Interleukin-15 biology and its therapeutic implications in cancer.
Trends Pharmacol Sci. 33:35–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baan CC, van Riemsdijk-Overbeeke IC,
Boelaars-van Haperen MJ, Ijzermans JM and Weimar W: Inhibition of
the IL-15 pathway in anti-CD25 mAb treated renal allograft
recipients. Transpl Immunol. 10:81–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith XG, Bolton EM and Bradley JA:
Targeting IL-15 as a therapeutic strategy in organ transplant
rejection. Curr Opin Investig Drugs. 3:406–410. 2002.PubMed/NCBI
|
|
18
|
Cho ML, Kim WU, Min SY, et al:
Cyclosporine differentially regulates interleukin-10,
interleukin-15, and tumor necrosis factor α production by
rheumatoid synoviocytes. Arthritis Rheum. 46:42–51. 2002.PubMed/NCBI
|
|
19
|
Lewis E, Weiler M, Chaimovitz C and
Douvdevani A: Interleukin-15 is the main mediator of lymphocyte
proliferation in cultures mixed with human kidney tubular
epithelial cells. Transplantation. 72:886–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stoeck M, Schäfer M, Hofmann HP and
Gekeler V: Dexamethasone and cyclosporin A do not inhibit
interleukin-15 expression in the human lung carcinoma cell line
A549. Eur Cytokine Netw. 11:414–419. 2000.PubMed/NCBI
|
|
21
|
Ono K and Lindsey ES: Improved technique
of heart transplantation in rats. J Thorac Cardiovasc Surg.
57:225–229. 1969.PubMed/NCBI
|
|
22
|
Giri JG, Ahdieh M, Eisenman J, et al:
Utilization of the beta and gamma chains of the IL-2 receptor by
the novel cytokine IL-15. EMBO J. 13:2822–2830. 1994.PubMed/NCBI
|
|
23
|
Hubscher SG: Histological findings in
liver allograft rejection - new insights into the pathogenesis of
hepatocellular damage in liver allografts. Histopathology.
18:377–383. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McCaughan GW, Davies JS, Waugh JA, et al:
A quantitative analysis of T lymphocyte populations in human liver
allografts undergoing rejection: the use of monoclonal antibodies
and double immunolabeling. Hepatology. 12:1305–1313. 1990.
View Article : Google Scholar
|
|
25
|
Wiederrecht G, Lam E, Hung S, Martin M and
Sigal N: The mechanism of action of FK-506 and cyclosporin A. Ann
NY Acad Sci. 696:9–19. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto S and Kato R: Hair
growth-stimulating effects of cyclosporin A and FK506, potent
immunosuppressants. J Dermatol Sci. (Suppl): S47–S54. 1994.
View Article : Google Scholar : PubMed/NCBI
|
